Rana Azfar, vice-president & general manager of Novo Nordisk Korea offers his impressions of the Korean market since moving from Pakistan. Azfar discusses how the most innovative insulin products have propelled Novo Nordisk forward in Korea, and how Novo Nordisk is working with patients and doctors to address the misconceptions around insulin treatments.
Currently, many multinationals in Korea are limiting their operations to the greatest extent possible, cutting head counts and prioritizing international partnerships to minimize liabilities. Novo Nordisk is moving in the opposite direction
